Neuro-Degenerative Disease Clinical Trial
Official title:
Efficacité du E-learning et du Jeu de rôle Pour la Formation Des Soignants Des EHPAD à l'Accompagnement de l'Agitation Dans Les Maladies neurodégénératives : Essai randomisé en Cluster
Verified date | January 2023 |
Source | University Hospital, Tours |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will investigate the effects of "I-Learn cognition and behaviour" training in the care in agitation in patients with neurodegenerative diseases. This training for caregivers, aims to reduce agitation and psycho-behavioral disorders of patients living in nursing home. In addition, amount of psychotropic drugs prescribed, as well as the number of hospitalizations during the study will be assessed.
Status | Completed |
Enrollment | 170 |
Est. completion date | January 9, 2023 |
Est. primary completion date | January 9, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Diagnosis of Major Neurocognitive Disorder according to DSM 5 - With agitation and NPI agitation item score of 4 or more (frequency X severity) - Information and verification of the non-opposition of the patient and his guardian / curator if he is under legal protection. Exclusion Criteria: - Patient under court protection - Inability to understand the French language - Patient whose state of health is not stabilised at the time of inclusion and/or in palliative care |
Country | Name | City | State |
---|---|---|---|
France | EHPAD Résidence du Prévot | Châteaugiron | |
France | Maison Saint Michel | Liffré | |
France | EHPAD La Bourdaisière | Montlouis-sur-Loire | |
France | Résidence Père Brottier | Pléchâtel | |
France | EHPAD Le Clos Saint-Vincent | Rochecorbon | |
France | EHPAD La Source | Tours | |
France | EHPAD Montconseil | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measurement of agitation of patients in the nursing home | Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation |
Baseline | |
Primary | Measurement of agitation of patients in the nursing home | Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation |
3 months | |
Primary | Measurement of agitation of patients in the nursing home | Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation |
6 months | |
Primary | Measurement of agitation of patients in the nursing home | Assessment of agitation using the Cohen-Mansfield Agitation Inventory (CMAI, 1989) by asking caregivers about the patients' behaviour.
The minimum value is 0 and the maximum value is 203. the higher the score, the more intense the agitation |
9 months | |
Secondary | Frequency and severity of Psychobehavioural Symptoms associated with Dementia | Assessment using the Neuro Psychiatric Inventory, care team version (NPI-ES, 2000). 10 behavioural domains and 2 neurovegetative variables are considered. item score = frequency x severity frequency minimum = 1 and maximum = 4 severity minimum = 1 and maximum = 3 A score above 2 is pathological | Baseline, 3 months, 6 months and 9 months | |
Secondary | Quality of life of patients | Assessment using the Quality of Life-Alzheimer's Disease (QOL-AD, 2009) 13 questions focus on the patient's quality of life. the patient's current quality of life in each domain is assessed by choosing one of the following four words: poor, fair, good, excellent. | Baseline, 3 months, 6 months and 9 months | |
Secondary | Impact of I-Learn on psychotropic drug prescriptions | Changes in the prescriptions given to patients in terms of psychotropic drugs (addition or withdrawal of a neuroleptic, antidepressant, anxiolytic, etc.) | Baseline, 3 months, 6 months and 9 months | |
Secondary | Impact of I-Learn on psychotropic drug prescriptions | Changes in the prescriptions given to patients in terms of dosage (increase/decrease of the daily dose) | Baseline, 3 months, 6 months and 9 months | |
Secondary | Impact of I-Learn training on hospital admissions | number of transfers to acute or emergency departments | 3 months, 6 months and 9 months | |
Secondary | Impact of I-Learn training on hospital admissions | reasons for hospitalisation | 3 months, 6 months and 9 months | |
Secondary | Impact of Psychobehavioural Symptoms Associated with Dementia on the professional practice of health care teams | Assessment using the Neuro Psychiatric Inventory, care team version (NPI-ES, 2000) 10 behavioural domains and 2 neurovegetative variables are considered. item score = frequency x severity fequency minimum = 1 and maximum = 4 severity minimum = 1 and maximum = 3 A score above 2 is pathological | Baseline, 3 months, 6 months and 9 months | |
Secondary | Caregiver burnout at work | Assessment using the Maslach Burnout Inventory (MBI, 1986) 22 items For each item, the minimum value is 0 and the maximum value is 6 BURNOUT Questions 1.2.3.6.8.13.14.16.20 Degree of burn out Total below 17 = low Total between 18 and 29 = moderate Total above 30 = high
DEPERSONALISATION Questions 5.10.11.15.22 Degree of burn out Total below 5 = low Total between 6 and 11 = moderate Total above 12 = high PERSONAL FULFILMENT Questions 4.7.9.12.17.18.19.21 Degree of burn out Total above 40 = low Total between 34 and 39 = moderate Total below 33 = high Moderate or even high scores are a sign of latent burnout that is taking hold. |
Baseline, 6 months and 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05586750 -
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
|
Phase 4 | |
Completed |
NCT04050800 -
Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety
|
Early Phase 1 | |
Recruiting |
NCT04863859 -
Persons With Dementia and Their Extended Family Caregivers
|
||
Recruiting |
NCT05655650 -
Identifying Biomarkers in Alzheimer's Disease
|
||
Enrolling by invitation |
NCT03197363 -
BiaĆystok PLUS - Polish Longitudinal University Study
|
||
Enrolling by invitation |
NCT03322306 -
Establishment of Genetic Basis for Neurological Disease by Genetic Screening
|
||
Completed |
NCT03439163 -
Large Sample PD Patients and Healthy Controls
|
N/A | |
Withdrawn |
NCT05921929 -
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
|
Phase 1 | |
Recruiting |
NCT05209698 -
Self-Management Behaviors of Arabs and Jews With Parkinson's Disease and Their Associations With Health Outcomes
|
||
Completed |
NCT04362228 -
The Effects of Whole-body Exercise to Improve Swallowing Function in Older Adults With Dementia
|
N/A | |
Enrolling by invitation |
NCT05008094 -
The Epidemiology of Parkinson's Disease in Croatia and the Influence of Genetic Factors and Microbiota on the Progression and Treatment Outcomes of the Disease (GiOPARK)
|
||
Completed |
NCT03279991 -
Neuromed- Integrated Health Life Platform and Biobank
|
||
Active, not recruiting |
NCT04228653 -
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
|
Phase 1/Phase 2 | |
Recruiting |
NCT05328492 -
Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis
|
N/A | |
Not yet recruiting |
NCT06151600 -
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
|
||
Recruiting |
NCT04880356 -
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
|
||
Active, not recruiting |
NCT03609125 -
Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma
|
N/A | |
Recruiting |
NCT03153670 -
3T MRI in Patients With Deep Brain Stimulation (DBS)
|
N/A | |
Completed |
NCT03775538 -
Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT04635540 -
Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease
|
N/A |